Evaluation of the antiinflammatory effect of the Vimang® cream in patients with Dermatitis chronic disease.
- Conditions
- Dermatitis Chronic diseaseSkin DiseasesDermatitis
- Registration Number
- RPCEC00000001
- Lead Sponsor
- Center of Pharmaceutical Chemistry
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
1. Pacients that sign the Informed Consent. 2. Patients with clinical and histological diagnosis of Dermatitis in chronic phase. The histologic study must be made at least 1 year before the inclusion. 3. Patients with extension of disease between the 2 and 30% of the affected corporal surface of agreement with the result obtained with the pattern of localization of the lesions. 4. Patients that could be receive ambulatory treatment.
1. Pregnancy, puerperal time or nursing. 2. Patients that have received another specific therapy for the Dermatitis during 10 previous days to the entrance in the study. 3. Patients with Dermatitis in acute phase or subacute. 4. Patients with steroid treatmemt. 5. Patients with illness chronic associate in acute phase(diabetes mellitus, renal chronic failure, hypertension, heart disease, severe psychiatric dysfunction or cancer) 6. Patients with acute severe infectious or in convalescence. 7. Patients with autoinmune diseases of any type. 8. The patient's negative to carry out protocolized studies. 9. Patients that are not corresponded the clinical study with the histological study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical evaluation through the method DASI (Dermatitis Assay Score Index). DASI will be evaluated in the first consultation and to the 6 weeks.
- Secondary Outcome Measures
Name Time Method It will be evaluated by interrogation and physical exam in weekly consultations during 6 weeks the presence of adverse effects: Pruritus Pain Ardor Blush Inflammation